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Abstract: Atherosclerosis (ATH) and coronary artery disease (CAD) are chronic inflammatory diseases
with an important genetic background; they derive from the cumulative effect of multiple common
risk alleles, most of which are located in genomic noncoding regions. These complex diseases
behave as nonlinear dynamical systems that show a high dependence on their initial conditions;
thus, long-term predictions of disease progression are unreliable. One likely possibility is that the
nonlinear nature of ATH could be dependent on nonlinear correlations in the structure of the human
genome. In this review, we show how chaos theory analysis has highlighted genomic regions that
have shared specific structural constraints, which could have a role in ATH progression. These regions
were shown to be enriched with repetitive sequences of the Alu family, genomic parasites that have
colonized the human genome, which show a particular secondary structure and are involved in
the regulation of gene expression. Here, we show the impact of Alu elements on the mechanisms
that regulate gene expression, especially highlighting the molecular mechanisms via which the Alu
elements alter the inflammatory response. We devote special attention to their relationship with the
long noncoding RNA (lncRNA); antisense noncoding RNA in the INK4 locus (ANRIL), a risk factor
for ATH; their role as microRNA (miRNA) sponges; and their ability to interfere with the regulatory
circuitry of the (nuclear factor kappa B) NF-κB response. We aim to characterize ATH as a nonlinear
dynamic system, in which small initial alterations in the expression of a number of repetitive elements
are somehow amplified to reach phenotypic significance.
Keywords: atherosclerosis; Alu repeats; noncoding RNAs; miRNA; miRNA sponge; ANRIL; chaos
theory; Chaos Game Representation; long-range correlations; NF-κB
1. Atherosclerosis Is a Complex Vascular Disease with Distinctive Traits of Nonlinear Behavior
Atherosclerosis (ATH) is a chronic inflammatory vascular disease that is characterized by the
interactions and feedback mechanisms involving lipids, cells, and various molecules and genetic
factors [1]. Many of these interactions are nonlinear, and are not proportional to the concentration
or density of the stimulus, as they may undergo sudden switches in response to small changes in
stimuli. For example, the rate at which the oxidized low-density lipoproteins (oxLDLs) are removed
by macrophages is limited by the number of available receptors in the cell membrane [2], and by the
complex networks of regulatory and environmental factors [3]. Thus, a systems biology approach
through the integration of data from large-scale measurements, such as transcriptomics, proteomics,
and genomics, might contribute to the unraveling of the regulatory networks underlying the responses
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of a wide variety of cellular systems [3]. Mathematical and computational models of such systems
show that these effects are not random, but instead, they are qualitatively predictable [4].
Recently, a computational model for plaque development was proposed. This model included
32 immunological parameters that were related to the action of monocytes and macrophages, foam cells,
macrophage chemoattractants, endothelium-stimulating cytokines, modified low-density lipoproteins,
and high-density lipoproteins (HDLs), as well as the timing of changes in the rate of HDL influx [2].
This model assumed that an injured endothelium would be sufficient for the development of plaques,
highlighting the immunological processes that occurred within the arterial walls. Although the model
only affords qualitative insight, because of the difficulty in obtaining valid values for all of the required
parameters for a quantitative model, it suggests that the nonlinear behavior that is exhibited in the
HDL dynamics may lead to sudden changes in plaque behavior [2]. This nonlinear system occurs
after periods of growth and equilibrium, in which the plaque environment is altered either because of
changes in the composition and function of HDLs with age [5], or to decrease the LDL influx following
successful treatment with statins [2].
Some studies have suggested that plaque morphology and biomechanical stress should also be
considered as major determinants of plaque vulnerability [6]. Thus, some computational models
of blood flow–plaque interactions included data from high-resolution magnetic resonance imaging
(MRI), allowing the noninvasive characterization of the plaque geometry. These data also suggested
that substantial variations in stress or strain in the plaque under pulsating pressures may lead to
plaque rupture [6]. On the other hand, recognition of the main roles of inflammation and immunity in
the initiation and progression of ATH has led to the development of mathematical models based on
reaction–diffusion equations [7]. Some mathematical models describing the early stage of ATH
were developed in an effort to study the recruitment of immune cells from the blood flow via
inflammatory cytokines, demonstrating that the chronic inflammatory reaction was developed akin
to the propagation of a traveling wave [7]. However, these simplified mathematical models only
studied particular aspects of the complex process that was giving rise to ATH, and a comprehensive
mathematical model explaining the entirety of the process remains elusive.
Vascular dynamics is also a nonlinear system, showing the time-dependent functional changes
that are critically dependent on interactions with various physical forces. These can be described as
either extra-tissular (blood flow oscillations, arterial pressure, etc.) or intra-tissular (calcifications, tissue
thickness, presence of white cell infiltrates, etc.); however, all of the cases demonstrate an unpredictable
evolution as a result of the appearance of minor interferences, with the potential of producing unforeseen
outcomes [8]. In this sense, the vascular dynamics can be considered as a “chaotic” system, whose
evolution demonstrates a very sensitive dependence on its initial conditions, and follows an uncertain,
nonlinear progression [3,8,9]. There are a number of reports supporting this hypothesis. As an example,
Bruschke et al. showed that the ATH progression in coronary arteries was a highly unpredictable process
that followed a nonlinear course [10], while other studies described the arteries as exhibiting a nonlinear,
elastic behavior [11]. Furthermore, carotid arteries exhibited nonlinear variations of circumferential
stress and tangent elastic moduli, within the normal pressure range [12], and the evolution of the
buckling pressures of arteries under pulsatile pressure conditions was accurately described, using a
nonlinear model of elasticity [13]. Lastly, nonlinear models were also used to study the effects of luminal
stenosis (and plaque morphology) on plaque stability [14], as well as the interactions between the elastic
layer (extracellular matrix (ECM) cap) and the rigid, calcified cells [15].
The majority of the above mentioned studies achieved the characterization of the chaotic behavior
of ATH through the unique incorporation of blood flow physics, and its role in the onset and
progression of the disease. Nevertheless, there were hints that the nonlinear progression of ATH
could also be derived from specific features in regions of the genome encoding the tissues that were
involved in ATH, although it is difficult to envision how differential dynamics could be generated in
a structure that is as homogeneous and tightly controlled as the mammalian nucleus. In this regard,
Xiao et al., through the implementation of a nonlinear prediction method, highlighted a subset of
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genomic sequences with novel deterministic structures, and nonlinear correlations that were essentially
different to those of the exonic and intronic sequences (see Reference [16], and Section 2 for a more
in-depth discussion on this topic). These sequences corresponded to members of the Alu family of
repeated elements, which consisted of short DNA sequences [17] that were involved in the regulation
of gene expression [18]. The Alu elements were found to be pervasively transcribed in a number of
physiological and clinical conditions [19–21], and were associated with various human diseases and
genetic disorders [22,23].
The nonlinear structural features of Alu elements make them worth studying, in an effort to
characterize their potential involvement in the generation of a chaotic progression during ATH
development. In this review, we describe the possible relationship between the Alu repeats and the
onset and evolution of ATH, specifically focusing on the unique structural and/or functional features
of Alu elements, which could contribute to the nonlinear progression of ATH. The three features that
were of the most interest were (i) the potential for the Alu transcripts to act as microRNA (miRNA)
sponges, and hence, impact the general levels of messenger RNA (mRNA) expression; (ii) their ability
to generate new regulatory networks via retrotransposition to the gene regulatory sites; and (iii) their
disruptive effect on the function of the cardiovascular disease (CVD)-associated long noncoding RNA
(lncRNA), antisense noncoding RNA in the INK4 locus (ANRIL), which was a strong risk factor that
was associated with ATH.
2. Multifractal and Chaos-Theory Analysis of the Human Genome Highlights the Involvement of
Alu Elements in the Development of Complex, Nonlinear Human Diseases
In Section 1, we drew attention to the various ATH-related physical features, in which disease
progression was not directly proportional to the intensity of the physical insults, suggesting that such
factors could possibly play a role in the nonlinear nature of ATH. However, we can just as easily
hypothesize that ATH evolution is dependent on the nonlinear correlations in the structure of the
human genome. In this section, we review a number of mathematical tools and methods (Chaos Game
Representation, multifractal analysis, and the detection of long-range correlations), which were applied
to the study of the human genome, and gives rise to a role for repetitive elements in the establishment
of the nonlinear statistical properties of human genomic DNA.
2.1. Chaos Theory Provides Tools for the Analysis of Global Genomic Signatures
The human genome is one of the most intricate molecular machines known to man, and a wide
range of approaches are used to study and analyze its complexity. Chaos theory and the Chaos Game
Representation (CGR) are two mathematical tools that are often used to characterize highly complex
systems. CGR, a combined implementation of chaos theory and chaotic dynamics, is an algorithm
that is used for the graphical representation of DNA sequences [24]. The CGR is presented as a
scatter plot, in which each point of the plot corresponds to each base in the sequence, thus producing
a complex picture of the DNA sequence, in which the local and global patterns of the sequential
structure can be defined [24]. In this sense, the CGR represents the statistical properties of the base
frequencies as intrinsic properties of the DNA sequence itself [24]. The main interest in the CGR
plots and their development [25] stems from their ability to reduce complex DNA sequences into
simple visual patterns, facilitating comparative studies of genomic signatures, as well as the analysis
of characteristic sequence motifs [26]. In this way, the CGR plots were used to determine not only the
degree of variability within and between genomes [27], but also to screen two complete genomes for
the presence of mismatches, insertions, or deletions [28,29].
Images that are produced by the CGR can be further broken down through methods that are
derived from fractal geometry (multifractal analysis) [24,27]. This approach is especially suited for the
analysis of very long strings of information, as it relies on the determination of intrinsic patterns, and
has proven useful in revealing the complex motifs in sequences [30]. Pioneering work by Yu et al. has
shown that genomic DNA sequences that are isolated from various microorganisms were not random
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sequences, but contrarily, exhibited strong long-range correlations [31] that were characterizable
through multifractal analysis [30]. Later on, the use of multifractal methods was established for the
analysis of the human genome [32,33]. Since then, multifractal analysis was used to differentiate
between coding and noncoding DNA sequences in humans [34] and bacteria [35], to predict human
promoter regions [36], to characterize complete genomes in C. elegans and humans [37,38], to perform
fast comparisons of the microbial genomes among them [39], to distinguish among isolates of
M. tuberculosis [40], and even to study the high order of the chromatin structure [38].
CGR and multifractal analysis were also applied to the analysis of protein sequences.
Specifically, Yu et al. studied a large number of protein sequences that were derived from
corresponding complete genomes, and demonstrated that these protein sequences were, in fact,
not completely random in nature [41]. Further developments allowed for the prediction of novel
structures of G-protein-coupled receptors (GPCRs) from amino acid sequences, despite the poor degree
of homology among them [42], as well as the construction of phylogenetic trees for bacteria, through
the use of protein sequences from complete genomes and CGR-based modeling [41].
2.2. Mathematical Analysis of the Human Genome Highlights Features of Nonlinear Correlations in the Alu
Family of Genomic Elements
The first report of nonlinear correlations in the human genome was put forward by Xiao et al.,
who used a chaos theory-derived nonlinear prediction method to differentiate between “random” and
“non-random” (deterministic) DNA sequences [16]. In their analysis, the authors studied the β-globin
locus, which encodes six globin genes (along with their exons and introns), and is enriched with a
family of repeated nuclear sequences, named Alu repeats (see Section 3). The authors demonstrated
that the exonic and intronic sequences in the β-globin locus did not show any significant deviation
from a random nature, while the sequences harboring these Alu repeated nuclear elements presented
nonlinear (deterministic) structures, likely because of a dimeric structure [16]. This intriguing result
was eventually confirmed through further work by Moreno et al., who reported that the human
genome displayed multifractal behavior, rich in highly polymorphic sequences that were organized
into a wide range of combinations [43]. Indeed, this multifractal structure was also seen to be strongly
dependent on the presence of Alu elements, and more specifically, on the content of Alu-S, the oldest
and most abundant of the Alu family [43].
Another tool that has been used to determine nonlinear statistical properties of DNA sequences
is called the “DNA walk”. This analytical method provides a quantitative measure of nucleotide
correlation across large distances along the DNA sequence, and has revealed the existence of long-range
power–law correlations, which are found exclusively in noncoding regions [44]. This concept was later
used to distinguish these regions from protein-coding regions [45]. Although conceptually complex,
DNA walks have been interpreted through a multi-level approach. Firstly, the application of DNA walk
algorithms to a long DNA sequence (from a chromosome or an entire genome) generates a number of
DNA domains in varying sizes, with a range of nucleotide concentrations. Secondly, the long-range
correlations identify distant domains with a certain degree of homology. Lastly, the power–law
correlation indicates whether or not these distances have followed a nonlinear distribution at the level
of either the chromosome or the genome [46]. On this basis, the genomic properties could be partially
explained by the presence of clustered repetitive elements, as they would feature in the nuclei of the
identified homologous sequences in different DNA domains. Indeed, this seemed to be the case as in a
recent body of work, where Sellis et al. showed the existence of power–laws in the size distribution
of the lengths separating the consecutive repeats of most of the Alu (and long interspersed nuclear
element (LINE)) elements in human chromosomes [47]. Despite this, other authors considered that the
Alu repeats only contributed weakly to these long-range correlations [48]. Surely, these differences in
opinion could be explained by the use of different methods and different DNA sequences [49].
The nonlinear correlations discussed above highlighted the Alu repeats as a factor contributing
to the nonlinear properties of the DNA sequences. Therefore, Alu repeats could be considered as
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genomic parasites, which repeatedly colonized the human genome. Consequently, these events are
highly heterogeneous, as a result of the sequence divergence that is dependent on the time at which
they were retrotransposed into the genome [17]. The work by Xiao et al. also reflected the distinctive
biological functions of Alu repeats, on the basis of their dimeric structures, which is reflected in
their three-dimensional folding [16]. This dimerization is rather complex as it is formed via two
independent 7SL RNA-like folding units (components of the signal recognition particle (SRP)), as well
as an inter-domain subunit between the two Alu arms [50,51] (Figure 1). In the following sections, we
address a number of mechanisms through which the highly heterogeneous Alu elements may impact
the ATH progression, focusing on the mechanisms through which these Alu repeats may affect the
gene expression. We also distinguish between the involvement of Alu-RNAs and genome-embedded
Alu elements in these mechanisms.
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“junk ” [52]. ccording to the latest human GENCODE release (version 28, November 2017),
the human genome is composed of fewer than 20,000 protein-coding genes (i.e., a mere 2% of the
total genome’s length) [53], in addition to more than 40,000 transcriptional units for previously
unclassified non-protein-coding RNAs and pseudogenes (www.gencodegenes.org/stats/current.html).
These ncRNAs can be loosely classified into three basic categories, which have been listed below.
(i) ousekeeping , na ely, r (riboso al ), t (transfer ), sno (s all
nucleolar ), sn (s all nuclear ), , S P (single recognition particle ),
and 7S [54].
(ii) Long noncoding RNA (lncRNA, greater than 200 nt), which can be further divided into intronic
long intergenic ncRNAs (lincRNA), antisense transcripts from coding regions (antisense transcripts
from coding regions (asRNA), which do not encode proteins), circular ncRNA (circ ) [55], and
LINEs (long interspersed nuclear elements) [56], etc.
(iii) Short ncRNA (smaller than 200–300 nt), including microRNA (miRNA) [57], Piwi-interacting
RNA (piRNA) [58], and retrotransposon-derived ncRNA, such as short interspersed nuclear elements
(SINEs) [59]. Retrotransposon-derived repetitive sequences account for over 50% of the human
genome [60].
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3.2. Alu Repeats: A Family of Highly Succesful Genomic Invaders
The most abundant group of genes encoding ncRNAs are the Alu family, a member of the SINE
family. Alu repeats are established as significantly responsible for the regulation of gene expression
and the maintenance of genomic integrity. Considering that Alu elements are usually found nearby the
gene-rich regions, these repeated elements were shown to impact the regulation of gene expression
on both a transcriptional and post-transcriptional level, through various mechanisms [61]. The Alu
elements are over 300 bp long, and are dimeric retrotransposons composed of two arms, separated
by an A-rich linker (Figure 1). Alu repeats can be considered as highly successful genomic parasites,
which have colonized the human genome, through multiple cycles of retrotranscription (RNA to
complementary DNA, cDNA), insertion (cDNA into genomic DNA), and transcription (DNA to
RNA), to the extent that approximately one million copies are currently identifiable in the human
genome [62]. This means that over 10% of the human genome is composed of Alu repeats, which are
especially present in gene-rich regions, and that circa 30% of human genes harbor some copy of an Alu
element [63]. Based on their evolutionary history, Alu elements are classified into 12 subfamilies [64],
from which only one is currently deemed transpositionally active, while the remainder are inactive,
mainly because of 5′ truncation, but also because of sequence degeneration [65]. Alu elements are
non-autonomous, meaning their reverse transcription and integration into the genome requires the
protein machinery of other autonomous retrotransposons, such as LINEs (long interspersed nuclear
elements). However, under normal conditions, LINEs are also repressed in the human genome, mostly
through promoter methylation [66,67], thus indirectly contributing to the silencing of Alu elements.
Finally, Alu elements have the potential for also modifying the maturation process of mRNAs. On this
note, many Alu elements were detected in intronic regions [68], where they could provide new signals,
resulting in alternative mRNA splicings or even exon skipping [69], or where they can be incorporated
into mature mRNAs as “bona fide” exons, either on their own (Alu exonization), or after retaining part
of the neighboring intron (Alu-dependent intronic retention) [70].
3.3. Mature Alu-RNAs Include Free Alu Elements Transcribed by RNA Polymerase III, or mRNA-Embedded
Alu Elements Transcribed by RNA Polymerase II
Genomic Alu repeats include a bipartite polymerase III (Pol III) internal promoter at the 5′ end
of the left arm, and a short poly-A tail at the 3′ end of the right arm [18] (Figure 1). This allows
their transcription by RNA Pol III through this internal promoter, usually in response to cellular
stress [71–73]. This process creates “free” Alu elements in the form of individual Alu-RNA sequences,
or alternatively, concatemers of individual Alu-RNAs of a yet defined function, which have been
detected and cloned in cancer cells [21]. Furthermore, a number of “embedded” Alu elements were
also detected in mature mRNAs, usually in their 5′ or 3′ untranslated regions (UTRs) [18], with their
levels subject to regulation, based on reports of downregulation in cancer cells [74].
Interestingly, these free Alu elements have the potential for impacting the mRNA synthesis, as
they were shown to repress RNA Pol II-mediated transcription through the binding of the Pol II
initiation complex [18,75]. Furthermore, these free Alu elements were considered as probable miRNA
targets, likely acting as “miRNA sponges” (Figure 2) [76], and were involved in the regulation of
circRNA function circRNA [63] and mRNA stability [17]. In summary, because of their high copy
number, their internal promoters, and their embedment into mature transcripts, Alu elements are able
to impact most of the mechanisms regulating the RNA expression.
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progression. (A) Alu elements regulate the function of antisense noncoding RNA in the INK4 locus (ANRIL),
a risk factor for atherosclerosis and cardiovascular disease (CVD). ANRIL RNA, which harbors Alu
elements, is transcribed, recruiting polycomb repressive complexes 1 and 2 (PCR1/2), and interacting with
other genes via an “Alu–Alu” or “Alu–alternative site” direct interaction, thus facilitating the regulation of
their expression through PRC1/2. Taken from Reference [77]. Graphic not drawn to scale. (B). Alu-RNAs
could behave as microRNA (miRNA) sponges, creating complex regulatory networks that are altered
in diseases. Shown here are the main elements implicated in the Alu/miRNA regulatory loop, namely:
Alu genes, free Alu-RNAs, miRNA genes, and miRNAs. The postulated Alu–miRNA interaction does not
consider the folding of Alu elements, nor does it consider the existence of Alu miRNA-binding proteins that
could impact the interaction. STRESS stands for any stimulus that upregulates the transcription of free Alu
elements, such as glucocorticoids [78], human immunodeficiency virus (HIV) infection [79], adenovirus
type 5 [80] or type 2 infections [71], herpes simplex virus infection [81], or heat shock [73]. Graphic not
drawn to sc l . (C). Several Alu elements are binding sites for transcription factors, such as nuclear f ctor
kappa B (NF-κB), and may impact the gene expression of the inflammatory r sponse. Retrogressed Alu
elements ca function as NF-κB binding site , hus expanding the s t of genes co-regulated by NF-κB in
the inflammatory response (see main text for details). Shown her are the main elements implicated in the
Alu/NF-κB regulatory loop, namely: Alu genes, free Alu-RNAs, Alu complementary s (cDNAs), and
their etrogression to gene regulatory regions. STRESS is defined as in (B). D shed arrow sho s a new
Alu-derived regulatory site (Alu-κB). Graphic not drawn to scale.
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3.4. Genomic Alu Elements Are Involved in Transcriptional Regulation and Have an Impact on Human Disease
As previously stated, roughly one million Alu elements have colonized the human genome via
retrotransposition, mostly to gene-rich regions. This invasive process not only had a major impact
on the structure of the human genome in normal conditions (health), but also reshaped the genomic
landscape for diseases. The first consideration involves the benefits or requirements of an “open”
accessible chromatin structure, which the retrotransposition process requires, resulting in retrogressed
elements tending to concentrate in regulatory or gene-rich regions. On this topic, a recent work
by Gu et al. used technologies based on chromosome conformation capture to demonstrate that
the density of Alu elements correlated strongly and positively with those of the functional DNA
elements, such as enhancers and promoters [82]. Furthermore, there is also functional evidence of the
integration of Alu elements into human genomic regulatory regions. Without delving into the details, a
T-cell-specific enhancer containing an Alu element was located in the final intron of the human cluster
of differentiation 8 (CD8) alpha gene [83], while other nearby repetitive Alu elements were able to
form a cruciform structure, regulating the function of the CD8 alpha enhancer [84]. Additionally, the
human growth hormone (HGH) gene was shown to contain a functional silencing element within an
Alu repeat in its 3′-flanking region [85]. This close involvement of the Alu elements with regulatory
regions led several authors to propose that retrogressed Alu repeats could form the foundation for
new functional sites, such as the Pol II transcription factor binding sites, which would contribute
to the generation of new regulatory networks [76], cryptic/alternative splice sites [86], or nuclear
receptor binding sites [87]. Therefore, Alu elements could be considered as a large reservoir of potential
regulatory functions, contributing to the evolution of mechanisms regulating gene expression [69], or
even to the creation of novel functional genes [88].
On the other hand, Alu elements were also found to be related to the onset of a number of human
diseases [22,70] via different mechanisms. These included genetic deletions and duplications [89],
insertional mutagenesis [90], or the alteration of methylation patterns in DNA [91]. Correspondingly,
genomic regions that were highly enriched with Alu elements were considered as intrinsically unstable,
since they were targeted by homologous recombination machinery, because of the high homology
among the Alu sequences [92]. For example, a retroinserted Alu element was shown to be the root of
neurofibromatosis 1 (NF1), via the inactivation of a downstream exon during splicing, consequently
shifting the reading frame of the NF1 gene [93]. Additionally, a deletion that occurred between
two Alu repetitive sequences in the same orientation, was shown to inactivate the low-density
lipoprotein (LDL) receptor gene in Korean patients suffering familial hypercholesterolemia (FH) [94].
Finally, Alu-mediated recombinations (leading to exon skipping) were implicated in the origin of
Hunter disease [95,96].
4. Anril: A Long Noncoding RNA Harboring a Risk Factor for Atherosclerosis
Coronary artery disease (CAD) has a heritable trait [97], that is associated with a number of
genetic variants [98], and up to 43.5% of the variation in the level of coronary artery calcification
(CAC) is attributable to genetic factors [99]. Various genome-wide association studies (GWAS)
have identified a strong association between a risk of CAD and a large (58 kbp) intergenic
locus at chromosome 9p21 [100] in multiple human populations, including South Koreans [101],
Italians [102], Japanese and Koreans [103], American Caucasians [104], Chinese Hans [105], North
Indians [106], and Americans of African ancestry [107], among others, while a number of recent
meta-analyses have confirmed this association [108–111]. This region of the chromosome includes
several single-nucleotide polymorphisms (SNPs), featuring a tight linkage disequilibrium, disrupting
predicted transcription-factor binding sites involved in key physiological processes [112,113]. On a
genomic level, the 9p21 risk locus is a protein-coding gene-free region, encoding a long noncoding
RNA (lncRNA) called ANRIL/CDKN2B-AS1 (antisense noncoding RNA in the INK4 locus, or CDKN2B
antisense 1), which was identified as a genetic factor associated with cardiovascular morbidity and
mortality [114], also correlating with ATH severity [77]. More recently, a targeted deletion of the 9p21
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locus was reported, which led to a less stable phenotype in the artery [115], a dependence of diastolic
blood pressure and CAC on genetic variation within the ANRIL locus [116], and the overexpression of
ANRIL in ATH-arteries when compared with non-ATH counterparts [117].
In the 9p21 region, ANRIL is found relatively far away (over 100 kbp) from the cyclin-dependent
kinase inhibitor gene cluster p15/CDKN2B-p16/CDKN2A-p14/ARF, despite the first ANRIL exon being
located adjacent to the p14/ARF promoter, overlapping two p15/CDKN2B exons [118]. To date, any
other transcript remains undetected in this genomic region. Since long ncRNAs are implicated in the
regulation of most mechanisms of gene expression, whether transcriptional or post-transcriptional
(translational), as well as in the control of mRNA stability, pre-miRNA processing, and chromatin
structure [119], the many mechanisms via which ANRIL can exert are expectedly diverse [120].
Correspondingly, ANRIL reportedly behaves as a miRNA sponge in various diseases, through
the targeting of miR-199a [121], miR-125a [122], miR-186 [123], and miR-323 [124], among others.
Furthermore, ANRIL was also described as a regulator of various signaling pathways, including the
ataxia telangiectasia mutated (ATM)/E2F1 pathway [125], the vascular endothelial growth factor
(VEGF) pathway [126], and the nuclear factor kappa B (NF-κB) pathway [127]. ANRIL was also found
to regulate the cell cycle by interfering with the expression of the p15/CDKN2B-p16/CDKN2A-p14/ARF
locus. ANRIL overexpression was also correlated with the downregulation of p16(INK4a) [128] and
p15(INK4b) [129], and was shown to upregulate a number of genes that were involved in proliferation,
adhesion, and apoptosis in monocytes [77]. Furthermore, the depletion and mutagenesis of ANRIL
reversed the trans-regulation of these genes, and normalized the cellular functions [77].
On the other hand, a number of ANRIL splicing isoforms were described [77], whose expression,
which included exons proximal to the INK4/ARF locus, was correlated with an increased risk of
atherosclerotic vascular disease (ASVD) [130,131]. ANRIL risk alleles were also associated with
inflammatory response, as they were shown to disrupt a binding site for the signal transducer
and activator of transcription 1 (STAT1) protein, which was responsible for the mediation of the
transcriptional response to the gamma interferon (γ-IFN) [132]. Furthermore, it was also suggested
that SNPs in risk alleles could alter the profile of the ANRIL isoforms at the splicing level, or
by generating circular forms of ANRIL, which would impact the expression of the neighbouring
p15/CDKN2B-p16/CDKN2A-p14/ARF locus [133]. Correspondingly, our group reported that the ANRIL
SNP rs10757278 (GG) doubled the risk of major adverse cardiovascular events (MACEs) in patients
with chronic kidney disease (CKD) who were on hemodialysis, via an unknown mechanism [134].
Finally, a recent report revealed an unsuspected functional relationship among ANRIL and the
members of the Alu family of repeated sequences, whereby a new regulatory tier was added to the
ANRIL activity by Alu elements, which impacted the cells’ ability to adhere and proliferate, and
facilitated the ATH progression (Figure 2) [77].
5. Alu Elements May Play Multiple Roles in the Progression of Atherosclerosis
Alu repeated elements are connected with ATH progression in a variety of ways, and in this
section, we review the most significant of these. From Alu-RNAs (whether free or embedded) to Alu
genomic elements (with various localizations), the Alu repeated elements potentially impact a wide
range of mechanisms, ensuring the accuracy of gene expression, which can be altered in diseases.
Focusing on ATH, we discuss the relationships between the Alu elements and two other families
of ncRNAs, with a known involvement in ATH progression, namely, a group of small microRNAs
(miRNAs), and the lncRNA ANRIL, with specific alleles that have been acknowledged as risk factors
for CAD (see Section 4).
miRNAs are a class of short ncRNAs (20–22 nucleotides long) that regulate the stability of most of
the coding transcripts through the binding of the 3′ UTR of target mRNAs; however, this interaction is
highly complex and it is not completely understood [135]. A number of experimental models have
highlighted a direct link between the altered miRNA expression and the onset and progression of
ATH [135–137]. Moreover, miR-21, miR-126, and miR-155 were all characterized as regulators of vessel
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remodeling [138], while miR-21 and miR-155 were found to regulate foam-cell formation [135,139],
as well as miR-9, miR-125a-5p, and miR-155, which were all identified as being responsible for the
regulation of the lipid uptake by macrophages [140]. Furthermore, miR-33, miR-106, miR-122, and
miR-144 were shown to control lipid homeostasis, and miR-758 apparently targeted the transcripts that
were involved in cholesterol metabolism and fatty acid oxidation [137]. Finally, miR-17-5p, miR-20a,
miR-106a, and miR-424 were all shown to regulate monocyte/macrophage differentiation [138].
The expression of miR-125b is related to ATH through its ability to downregulate the expression
of podocalyxin (PODXL), an adhesion molecule of endothelial cells [141]. We demonstrated the
upregulation of miR-125b in an experimental model of ATH progression and in human ATH
plaques [142], and these changes were reversed upon CD40 silencing [142].
5.1. Role of Alu Elements in the Regulation of ANRIL Function
The great interest in ANRIL in the context of CAD research arises from this locus harboring a
risk allele that is strongly associated with ATH [143]. Recent work has highlighted a link between
the regulation of the ANRIL function and the presence of Alu elements [77,143]. In this work, the
authors firstly performed an expression analysis in an effort to characterize the pattern of the ANRIL
isoforms that were expressed in human peripheral blood mononuclear cells (PBMCs), and in the
monocyte cell line, MonoMac. The subsequent analysis of the ANRIL expression in CAD patients and
control patients demonstrated that the ANRIL expression was significantly increased in the samples
harbouring the risk allele. The ANRIL overexpression had also caused the upregulation of other
mRNA transcripts that were related to cell adhesion, growth, and proliferation, an effect that was
reversible via the downregulation of ANRIL with a specific small interfering RNA (siRNA) [143].
The mechanism through which ANRIL was able to trans-regulate the expression of a number of genes
required the binding of polycomb repressive complexes 1 and 2 (PRC1/2), CBX7, SUZ12, and others, to
ANRIL. These proteins were recruited to the promoters of their target genes upon ANRIL expression.
A bioinformatic analysis of ANRIL and of the promoter regions of the ANRIL-targeted genes highlighted
a common presence of Alu elements in both, suggesting that ANRIL might bind to chromatin through
an Alu-mediated interaction, guiding the PRC proteins to ANRIL-regulated genes, so as to modify
their expression. In this way, the ANRIL overexpression could increase the cell proliferation and
adhesion, and decrease apoptosis, thus modulating pro-atherogenic cell functions. Contrarily, the
ANRIL silencing reversed the trans-regulation and normalized the cellular functions [143] (Figure 2A).
The ANRIL murine orthologous sequence was encoded in chromosome 4 [144], although the
locus was not fully conserved between mice and humans [145]. Interestingly, a murine mutant
showing a 70 kb deletion of noncoding DNA in the ANRIL locus, which included the risk allele,
showed a markedly decreased expression of Cdkn2a and Cdka2b, as well as an increased proliferation
and diminished senescence of primary aortic smooth muscle cells (SMCs) in the culture [144].
These findings strongly supported the hypothesis that the ANRIL locus could be implicated in the
pathogenesis of the CAD. Nevertheless, the fact that mice did not have bona fide Alu elements [146],
but rather, they had structurally related B1 elements (see Reference [147] for a recent review), made it
difficult to determine the mechanism of action, and to compare it with that of the human ANRIL.
5.2. Interaction between Alu-RNAs and miRNAs Creates Complex Regulatory Networks
Alu elements and miRNAs interact in multiple and complex ways, with the Alu elements being
a source of miRNAs, which, in turn, target the Alu sequences [148]. As previously stated, many of
the Alu elements that are embedded in the genome have functional RNA Pol III promoters, giving
them the ability to be transcribed autonomously and independently of the RNA Pol II transcriptional
machinery [18,75]. In a number of cases, these Alu promoters had also been seen to prime the RNA-Pol
III-dependent (Pol II-independent) transcription of miRNAs [149], and a recent bioinformatic analysis
showed that up to 5% of the intronic miRNA genes contained these upstream Pol III-dependent
Alu regulatory elements [150]. This could explain the discordant expression rates of some intronic
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miRNAs and their “host” genes. Unfortunately, only a few of these Pol III-dependent miRNAs are
currently functionally characterized [149]; however, over 50 miRNAs that were reliant on RNA Pol III
for expression were detected within the Alu repetitive elements [151].
Another example of Alu/miRNA cross-regulation comes from a reported epigenetic therapy of
human gastric tumors, which showed that a number of miRNAS were activated via Pol-II-dependent
transcription, upon treatment [152]. In this work, the authors showed that the most significant hit
(miR-512-5p) was located in close proximity to an Alu repeat, which behaved as an RNA Pol II
promoter [152]. Similarly, other Alu repeats were characterized as Pol II promoters in CpG islands in
human genes [153].
On the other hand, there were several reports on the mutual functional relationship between Alu
elements and miRNAs, resulting in the inactivation of one of these transcripts. Correspondingly, almost
30 human miRNAs were shown to exhibit a short-seed homology with highly conserved Alu sequence
elements located at the 3′ UTRs of human mRNAs [154], suggesting that these miRNAs could target
the mRNA through the Alu sequences. Daskalova et al. showed that the majority of the Alu sequences
that were inserted in the analyzed 3′ UTRs of the human genes carried strong potential target sites
for over 50 different miRNAs [155]. Furthermore, in an interesting development, Lehnert et al.
showed that the most common miRNA target site coincided with the most conserved sequence of
the Alu element [156]. More recently, Di Ruocco et al. showed that Alu-RNAs were able to induce
epithelial–mesenchymal transition (EMT) in colorectal cancer cell lines, by acting as a molecular sponge
of miR-566 [157]. Furthermore, miR-15a-3p and miR-302d-3p, which were upregulated during a stress
response, were shown to exclusively target the checkpoint DNA exonuclease (RAD1), the G2 and
S phase-expressed protein 1 (GTSE1), the nuclear receptor subfamily 2, group C, member 1 protein
(NR2C1), the FK506-binding protein 9 (FKBP9), and the ubiquitin-conjugating enzyme E2 (UBE2I),
within the Alu elements [158]. Additionally, miR-661 was found to target the MDM2 proto-oncogene
(Mdm2) and Mdm4, resulting in their downregulation, with a subsequent increase in p53 activity; the
inhibition of cell cycle progression in p53-proficient cells was also shown to occur within the Alu
elements [159]. In this context, and although much more work is required on the interaction between
the Alu-RNAs and miRNAs, we hypothesize that individual Alu-RNAs or mRNA-embedded Alu
elements could have an impact on ATH progression, by behaving as molecular sponges for specific
miRNAs that are involved in disease development (Figure 2B).
5.3. Alu Elements Are Common Binding Sites for Transcription Factors, Such as NF-κB, and May Impact Gene
Expression of the Inflammatory Response
NF-κB proteins are critical regulators of the immune response, with a substantiated role in ATH
progression in animal models of ASVD [160], and in human ASVD [161,162] patients. Activated NF-κB
was localized in vascular endothelial cells (VEC), smooth muscle cells (SMCs), and lymphocytes
in the vasa vasorum of the abdominal aortas, with atherosclerotic plaques that were isolated from
deceased patients [162]. NF-κB can be activated through two different pathways, one canonical and
the other non-canonical. In the canonical pathway, the NF-κB nuclear factors (RelA or p65, RelB, c-Rel,
p50, and p52) remained inactive in the cytoplasm by interacting with the inhibitor of kappa B (IκB)
proteins. The triggering of various receptors, including pattern recognition receptors (PRRs), tumor
necrosis factor receptors (TNFRs), T-cell receptors (TCRs), B-cell receptors (BCR), etc., activated the
IκB kinases (IKKs), which resulted in IκB phosphorylation, and subsequent proteasomal degradation,
thus facilitating the nuclear translocation of NF-κB RelA/p50, and the subsequent activation of the
NF-κB downstream target genes [163]. In the alternative, non-canonical NF-κB pathway, NF-κB
inducing kinase (NIK) activated IKKκ, which phosphorylated and processed p100 to p52, inducing the
formation of a transcriptionally active RelB/p52 complex [163]. On this topic, we recently described
the upregulation of the activator IKKκ gene and the downregulation of the IKBα inhibitor gene during
disease progression, in the experimental ApoE−/− model of ATH [142], suggesting the role of canonical
NF-κB activation in ATH progression.
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NF-κB nuclear factors (RelA, RelB, and c-Rel) had bound to the consensus κB site
(5′-GGGRNYYYCC-3′) in the promoters or enhancers of the target genes [163]. NF-κB was also
shown to bind to many non-consensus sites [164], of which nearly 10% were detected in Alu repetitive
elements, termed Alu-κB elements [165]. Although only a few of them were directly correlated with
changes in the expression of associated genes, it was suggested that these Alu-κB elements could
perform other cell type-specific functions, such as sequestering transcriptionally inert NF-κB molecules,
which would allow competent factors to activate target genes, but prevent the excessive targeting and
superactivation of promoters [165]. These data suggest that Alu elements, combined with other nearby
cis-acting elements, might play an important role in expanding the repertoire of the NF-κB binding
sites, allowing the engagement of new genes into NF-κB-dependent regulatory networks (Figure 2C).
Furthermore, the genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) in various
individuals and cell lines demonstrated that the NF-κB binding sites are polymorphic, and can differ
by over 7.5% among individuals. Most of these differences were as a result of SNPs in intergenic
regions, and were correlated with the differences in gene expression, indicating that the polymorphic
variation in binding sites could have functional consequences [166]. Although no data are available
on the extent to which the binding variation occurs in the Alu elements, it could be expected that
significant differences in transcription-factor binding sites, as well as in the gene expression between
individuals, are as a result of polymorphic Alu repeats.
5.4. A Polymorphic Alu Insertion Controls the Renin-Angiotensin System
It is known that elevated levels of angiotensin II (Ang II) contribute to vascular disease, and
that the kidney plays a critical role in the regulation of the renin–angiotensin–aldosterone system
(RAAS) [167]. Kidney renin is released into the blood, where it cleaves circulating angiotensinogen into
angiotensin I, which is subsequently transformed into angiotensin II by the angiotensin-converting
enzyme (ACE) that is produced in the vascular endothelium. Ang II may accelerate ATH progression
through the activation of factors, such as NF-κB, adhesion molecules, transforming growth factor
(TGF)-β, or endothelin-1, thereby inducing vascular growth, cell migration, and inflammation [168].
In addition, Ang II is a potent stimulus for pro-oxidant enzymes, leading to an increase in the
production of reactive oxygen species (ROS), and consequently, to increased oxidative stress. On the
contrary, blocking RAAS has demonstrated beneficial effects for the treatment of cardiovascular and
renal disease [169].
Alu elements are involved in the regulation of RAAS, and consequently, in the progress of
renal [170] and cardiovascular diseases [171], by virtue of a polymeric Alu insertion in intron 16 of the
ACE gene, giving rise to two different alleles, namely, the “insertion allele” (I allele) and the “deletion
allele” (D allele). The insertion allele of the Alu element (I allele) in the ACE gene resulted in an
open reading frame (ORF) shift, resulting in the premature termination of the ACE protein, and the
generation of a protein with a single active site in the N-terminal domain [69]. Homozygous D/D
individuals have plasma ACE levels that are about twice as high as those of the homozygous I/I
individuals [172], and also demonstrate diminished levels of tissue ACE [173]. Surprisingly, the
Alu repeat was found to also upregulate the transcriptional activity of the ACE promoter [174].
However, associated studies on the I/D polymorphisms of the ACE gene and cardiovascular outcomes
are still controversial because of the lack of powered studies and the existence of interactions with other
genes or environmental factors [175]. Furthermore, although a number of recent meta-analyses have
highlighted ACE I/D risk associations with hypertrophic cardiomyopathy [176], ischemic stroke [177],
and increased CKD [178], ethnicity still remains a strong confounder. This is evidenced by the
population-restricted associations that are described for the ACE I/D polymorphism, with susceptibility
to abdominal aortic aneurysms in European populations, but not in Asian populations [179]. On the
other hand, it was strongly associated with ischemic stroke in Asian populations, but had borderline
statistical significance for Caucasians [180].
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6. Concluding Remarks
Although great efforts were made to explore the landscape of the molecular alterations underlying
the development of ATH, and despite the wealth of knowledge that has been generated, we still
have a limited vision of most of the mechanisms that are involved in ATH development, as well
as their interactions or their mutual interferences. Clearly, new approaches for ATH research are
required in order to integrate new tiers of information and new regulatory layers. On this basis, the
chaos theory and the study of nonlinear dynamic systems offer new conceptual approaches, and
provide insight to better understand highly complex problems [181]. Chaotic systems, which can
be defined as deterministic but not predictable, are characterized by their exquisite sensitivity to
their initial conditions, and develop by following the trajectories of strange attractors of a fractal
nature [182]. A number of authors have proposed a chaotic component in the development of
atherosclerosis [183–185], a hypothesis that was subsequently confirmed by the work of Xiao et al.,
who used a chaos theory-derived nonlinear prediction method to highlight deterministic (non-random)
structures in the repetitive Alu elements. These structures were as a result of their dimeric composition,
a likely basis for nonlinear regulatory behaviour [16]. These results were further backed by Moreno et
al., who used a multifractal approach to study the human genome, showing that a multifractal pattern
was strongly correlated with the presence of repeated elements of the Alu family [43]. These works
made conceptual links between disease (ATH) and the overall structure of the human genome; they
also focused our attention on the functional involvement of Alu repeated elements in ATH progression.
In conclusion, the advent of the genomic revolution highlighted the involvement of noncoding DNAs
and RNAs in human diseases. Here, we reviewed the available data on the role of two such noncoding
nucleic acids—the lncRNA ANRIL, and the family of Alu repeated elements—on ATH onset and
progression. Although much research remains to be done on these (and other) noncoding elements, it
is becoming clear that the natural history of human disease is no longer simply a question of proteins
and coding genomic regions. Noncoding regions and long-range sequence correlations do, in fact,
have an important role in disease development.
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